Compare $ACXP vs $ALZN | Chartloom

Compare

$ACXP vs $ALZN

Acurx Pharmaceuticals Inc · Alzamend Neuro Inc

ACXP

Acurx Pharmaceuticals Inc

ALZN

Alzamend Neuro Inc

Compare $ACXP vs $ALZN

Comparing Acurx Pharmaceuticals Inc and Alzamend Neuro Inc

ACXPAcurx Pharmaceuticals Inc

ALZNAlzamend Neuro Inc

ACXPAcurx Pharmaceuticals Inc

Market cap

$5M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-54.0%

52W performance

-84.3%

FCF yield

-113.2%

ALZNAlzamend Neuro Inc

Market cap

$6M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-29.5%

52W performance

-47.0%

FCF yield

-106.6%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ACXP

ALZN

Detailed metrics comparison

ACXP

Acurx Pharmaceuticals Inc

ALZN

Alzamend Neuro Inc

Market Cap

ACXP$5M

ALZN$6M

Enterprise Value

ACXP$-5M

ALZN$-1M

Price

ACXP$1.27

ALZN$1.34

P/E Ratio

ACXPN/A

ALZNN/A

P/S Ratio

ACXP0.00x

ALZN0.00x

EV/Sales

ACXP0.00x

ALZN0.00x

EV/EBITDA

ACXP0.00x

ALZN0.00x

P/B Ratio

ACXP0.87x

ALZN1.14x

P/FCF Ratio

ACXPN/A

ALZNN/A

EV/FCF

ACXP0.84x

ALZN0.17x

PEG Ratio

ACXPN/A

ALZNN/A

Forward P/E (NTM)

ACXPN/A

ALZNN/A

Forward P/S (NTM)

ACXPN/A

ALZNN/A

Revenue (TTM)

ACXP$0

ALZN$0

Revenue Growth (YoY)

ACXPN/A

ALZNN/A

Forward Rev Growth

ACXP40.7%

ALZN0.0%

Gross Margin (TTM)

ACXP0.0%

ALZN0.0%

Operating Margin (TTM)

ACXP0.0%

ALZN0.0%

EBITDA Margin (TTM)

ACXP0.0%

ALZN0.0%

Net Margin (TTM)

ACXP0.0%

ALZN0.0%

FCF Margin (TTM)

ACXPN/A

ALZNN/A

Net Income (TTM)

ACXP$-8M

ALZN$-9M

FCF (TTM)

ACXP$-6M

ALZN$-7M

EPS (TTM)

ACXP-$1.76

ALZN-$2.03

ROE (TTM)

ACXP-12474.0%

ALZN-27788.0%

ROA (TTM)

ACXP-8749.0%

ALZN-18419.0%

ROIC (TTM)

ACXP-12474.0%

ALZN-27788.0%

Cash

ACXP$11M

ALZN$8M

Debt

ACXP$0

ALZN$0

Net Cash/Debt

ACXP$11M

ALZN$8M

Current Ratio (TTM)

ACXP3.88x

ALZN3.01x

Quick Ratio (TTM)

ACXP3.80x

ALZN2.77x

Debt/Equity (TTM)

ACXP0.00x

ALZN0.00x

Debt/Assets (TTM)

ACXP0.0%

ALZN0.0%

Interest Coverage (TTM)

ACXPN/A

ALZNN/A

Net Debt/EBITDA (TTM)

ACXP0.00x

ALZN0.00x

Beta

ACXP-2.14

ALZN0.43

52W Performance

ACXP-84.3%

ALZN-47.0%

YTD Performance

ACXP-54.0%

ALZN-29.5%

% from 52W High

ACXP-84.4%

ALZN-50.0%

% from 52W Low

ACXP3.3%

ALZN59.5%

Asset Turnover (TTM)

ACXP0.00x

ALZN0.00x

FCF Yield (TTM)

ACXP-113.2%

ALZN-106.6%

Earnings Yield (TTM)

ACXP-137.5%

ALZN-141.7%

Dividend Yield (TTM)

ACXPN/A

ALZNN/A

Rule of 40

ACXP0.0

ALZN0.0

EV/GP/RG

ACXPN/A

ALZNN/A

Ticker research

View ACXP research View ALZN research

Metric	ACXP Acurx Pharmaceuticals Inc	ALZN Alzamend Neuro Inc
Market & Valuation
Market Cap	$5M	$6M
Enterprise Value	$-5M	$-1M
Price	$1.27	$1.34
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	0.00x
EV/Sales	0.00x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.87x	1.14x
P/FCF Ratio	N/A	N/A
EV/FCF	0.84x	0.17x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	40.7%	0.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-8M	$-9M
FCF (TTM)	$-6M	$-7M
EPS (TTM)	-$1.76	-$2.03
ROE (TTM)	-12474.0%	-27788.0%
ROA (TTM)	-8749.0%	-18419.0%
ROIC (TTM)	-12474.0%	-27788.0%
Financial Health
Cash	$11M	$8M
Debt	$0	$0
Net Cash/Debt	$11M	$8M
Current Ratio (TTM)	3.88x	3.01x
Quick Ratio (TTM)	3.80x	2.77x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-2.14	0.43
52W Performance	-84.3%	-47.0%
YTD Performance	-54.0%	-29.5%
% from 52W High	-84.4%	-50.0%
% from 52W Low	3.3%	59.5%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-113.2%	-106.6%
Earnings Yield (TTM)	-137.5%	-141.7%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View ACXP research	View ALZN research

Valuation

P/S Ratio

ACXP

0.00x

ALZN

0.00x

EV/FCF

ALZN

0.17x

ACXP

0.84x

Growth & revenue

Forward Revenue Growth

ACXP

40.7%

ALZN

0.0%

Profitability & performance

Gross Margin

ACXP

0.0%

ALZN

0.0%

ROE

ACXP

-12474.0%

ALZN

-27788.0%

FCF Yield %

ALZN

-106.6%

ACXP

-113.2%

52-Week Performance

ALZN

-47.0%

ACXP

-84.3%

Detailed metrics comparison

ACXP

Acurx Pharmaceuticals Inc

ALZN

Alzamend Neuro Inc

Market Cap

ACXP$5M

ALZN$6M

Enterprise Value

ACXP$-5M

ALZN$-1M

Price

ACXP$1.27

ALZN$1.34

P/E Ratio

ACXPN/A

ALZNN/A

P/S Ratio

ACXP0.00x

ALZN0.00x

EV/Sales

ACXP0.00x

ALZN0.00x

EV/EBITDA

ACXP0.00x

ALZN0.00x

P/B Ratio

ACXP0.87x

ALZN1.14x

P/FCF Ratio

ACXPN/A

ALZNN/A

EV/FCF

ACXP0.84x

ALZN0.17x

PEG Ratio

ACXPN/A

ALZNN/A

Forward P/E (NTM)

ACXPN/A

ALZNN/A

Forward P/S (NTM)

ACXPN/A

ALZNN/A

Revenue (TTM)

ACXP$0

ALZN$0

Revenue Growth (YoY)

ACXPN/A

ALZNN/A

Forward Rev Growth

ACXP40.7%

ALZN0.0%

Gross Margin (TTM)

ACXP0.0%

ALZN0.0%

Operating Margin (TTM)

ACXP0.0%

ALZN0.0%

EBITDA Margin (TTM)

ACXP0.0%

ALZN0.0%

Net Margin (TTM)

ACXP0.0%

ALZN0.0%

FCF Margin (TTM)

ACXPN/A

ALZNN/A

Net Income (TTM)

ACXP$-8M

ALZN$-9M

FCF (TTM)

ACXP$-6M

ALZN$-7M

EPS (TTM)

ACXP-$1.76

ALZN-$2.03

ROE (TTM)

ACXP-12474.0%

ALZN-27788.0%

ROA (TTM)

ACXP-8749.0%

ALZN-18419.0%

ROIC (TTM)

ACXP-12474.0%

ALZN-27788.0%

Cash

ACXP$11M

ALZN$8M

Debt

ACXP$0

ALZN$0

Net Cash/Debt

ACXP$11M

ALZN$8M

Current Ratio (TTM)

ACXP3.88x

ALZN3.01x

Quick Ratio (TTM)

ACXP3.80x

ALZN2.77x

Debt/Equity (TTM)

ACXP0.00x

ALZN0.00x

Debt/Assets (TTM)

ACXP0.0%

ALZN0.0%

Interest Coverage (TTM)

ACXPN/A

ALZNN/A

Net Debt/EBITDA (TTM)

ACXP0.00x

ALZN0.00x

Beta

ACXP-2.14

ALZN0.43

52W Performance

ACXP-84.3%

ALZN-47.0%

YTD Performance

ACXP-54.0%

ALZN-29.5%

% from 52W High

ACXP-84.4%

ALZN-50.0%

% from 52W Low

ACXP3.3%

ALZN59.5%

Asset Turnover (TTM)

ACXP0.00x

ALZN0.00x

FCF Yield (TTM)

ACXP-113.2%

ALZN-106.6%

Earnings Yield (TTM)

ACXP-137.5%

ALZN-141.7%

Dividend Yield (TTM)

ACXPN/A

ALZNN/A

Rule of 40

ACXP0.0

ALZN0.0

EV/GP/RG

ACXPN/A

ALZNN/A

Ticker research

View ACXP research View ALZN research

Metric	ACXP Acurx Pharmaceuticals Inc	ALZN Alzamend Neuro Inc
Market & Valuation
Market Cap	$5M	$6M
Enterprise Value	$-5M	$-1M
Price	$1.27	$1.34
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	0.00x
EV/Sales	0.00x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.87x	1.14x
P/FCF Ratio	N/A	N/A
EV/FCF	0.84x	0.17x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	40.7%	0.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-8M	$-9M
FCF (TTM)	$-6M	$-7M
EPS (TTM)	-$1.76	-$2.03
ROE (TTM)	-12474.0%	-27788.0%
ROA (TTM)	-8749.0%	-18419.0%
ROIC (TTM)	-12474.0%	-27788.0%
Financial Health
Cash	$11M	$8M
Debt	$0	$0
Net Cash/Debt	$11M	$8M
Current Ratio (TTM)	3.88x	3.01x
Quick Ratio (TTM)	3.80x	2.77x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-2.14	0.43
52W Performance	-84.3%	-47.0%
YTD Performance	-54.0%	-29.5%
% from 52W High	-84.4%	-50.0%
% from 52W Low	3.3%	59.5%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-113.2%	-106.6%
Earnings Yield (TTM)	-137.5%	-141.7%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View ACXP research	View ALZN research